(Q33503017)

27 July 2017

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients (English)

1 reference

27 July 2017

hepatocellular carcinoma

1 reference

1 reference

1 reference

Chao Y

1

1 reference

27 July 2017

Chan WK

2

1 reference

27 July 2017

Birkhofer MJ

3

1 reference

27 July 2017

Hu OY

4

1 reference

27 July 2017

Wang SS

5

1 reference

27 July 2017

Huang YS

6

1 reference

27 July 2017

Liu M

7

1 reference

27 July 2017

Whang-Peng J

8

1 reference

27 July 2017

Chi KH

9

1 reference

27 July 2017

Lui WY

10

1 reference

27 July 2017

Lee SD

11

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

British Journal of Cancer

27 July 2017

1 reference

27 July 2017

78

1 reference

27 July 2017

1

1 reference

27 July 2017

34-39

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.438

27 July 2017

0 references

cites work

Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Treatment of hepatocellular carcinoma: too many options?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Clinical toxicities encountered with paclitaxel (Taxol).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Taxol: mechanisms of action and resistance.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Taxol: pharmacology, metabolism and clinical implications.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062942

Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan

31 October 2018

1 reference

12 December 2020

Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function

1 reference

12 December 2020

Expression of a multidrug resistance gene in human cancers

1 reference

12 December 2020

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

1 reference

12 December 2020

High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma

1 reference

12 December 2020

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

1 reference

12 December 2020

Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function?

1 reference

12 December 2020

The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.438

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference